Replies to post #211966 on Biotech Values

[DewDiligence]

MYL—The Copaxone discussion starts at 21:03 remaining in the GS webcast. MYL’s CEO claims the FDA’s “information request” was only for the 20mg ANDA, but common sense tells us that the 40mg ANDA can’t be approved before the 20mg ANDA, so both ANDAs are delayed for all practical purposes.

Direct link to the webcast:
https://cc.talkpoint.com/gold006/061317a_as/